BELGIAN77, you still with us? Big things around the corner.
"$13 million in gross proceeds, which we expect to provide sufficient capital to fully fund the Phase 2b clinical trial for BPX-01. Our topical formulation of minocycline and to advance some other products in our pipeline".
"Additionally, we recently received a patent approval on our novel micro particle encapsulation system, which allows the delivery of hydrophilic water sensitive agents in a hydrophobic encapsulant, which we also believe is well suited to address a large market in a novel way. We will be providing updates on these products in the future".
"we will evaluate a therapy for Rosacea and Impetigo, we will consider a lower dosage alternative through a small and relatively inexpensive clinical study".
"Vivo made a $6 million strategic investment in BioPharmX, currently making them our largest shareholder. This level of commitment by a knowledgeable experienced healthcare investor was particularly gratifying".
Um yeah, because a positive Phase IIB study is about to be completed!
On December 14, 2016, BioPharmX, Inc., a Nevada corporation and wholly-owned subsidiary of BioPharmX Corporation (“Company”), and Refuge Biotechnologies, Inc., a Delaware corporation, entered into a Sublease Agreement (“Sublease”) for the lease of approximately 12,066 square feet of office and laboratory space located at 1505 Adams Drive, Menlo Park, California, which will replace the Company’s current corporate headquarters. This facility will serve as the new principal executive office and laboratory for the Company.
Hope you're your still here with us longs, because I anticipate a terrific 2017 for all that have been continuously adding to this investment!
News 
Market Data 
Discover 
